Skip to content

Tricuspid Regurgitation Study

The Effect of Cardiac Pacing Leads on Tricuspid Regurgitation

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01093001
Enrollment
119
Registered
2010-03-25
Start date
2010-05-31
Completion date
2016-05-31
Last updated
2016-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tricuspid Regurgitation, Right Ventricular Dysfunction, Left Ventricular Dysfunction

Keywords

Reduce Tricuspid Regurgitation, Reduce Right Ventricular pacing, Lead position, Lead size

Brief summary

The effect of cardiac pacing leads on tricuspid regurgitation is unclear. This study will determine whether using a smaller diameter leads and an alternate position in the ventricle, the proximal septum, will reduce tricuspid regurgitation than larger leads placed in the apex.

Detailed description

Leads are commonly placed in the right ventricular apex. It is not known whether placing similar leads higher on the septum where there will be less redundancy or pressure on the septal leaflet will change the extent and severity of tricuspid regurgitation following pacemaker/ICD implantation. Data has shown that right ventricular pacing can give rise to right ventricular dysfunction, which in turn may give rise to enlargement of the right ventricle and cause tricuspid regurgitation. The study will answer the clinically relevant questions on device lead-related tricuspid regurgitation. This study is a single center prospective study at the Mayo Clinic, Rochester. The study will enroll 200 eligible subjects and follow for 12 months. 50 pacemaker subjects will be randomized to right ventricular apex pacing 50 pacemaker subjects will be randomized to right ventricular septum pacing 50 pacemaker subjects will be randomized to left ventricular pacing via coronary sinus 50 ICD subjects will be enrolled with right ventricular apex pacing. A baseline heart failure assessment and Two Dimensional echocardiography will be performed before device implant. A Two Dimensional echo will be performed 24 hours after device implant. If significance TR is present a Three Dimensional echo will be performed. At 12 months post implant heart failure assessment and Two Dimensional echo will be performed.

Interventions

OTHEREcho

Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.

Sponsors

Abbott Medical Devices
CollaboratorINDUSTRY
Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* 18 years of either sex * Patient is recommended to receive a pacemaker or an ICD * Provide informed consent

Exclusion criteria

* Pregnant or breastfeeding women * Congenital heart disease * Pre-existing moderate or severe TR * An existing pacemaker or defibrillator * Pulmonary hypertension * Pacemaker dependence * Unable to give informed consent * Not feasible for patient to be followed up at Mayo Clinic * Acute myocardial infarction within 7 days

Design outcomes

Primary

MeasureTime frame
Decrease in Tricuspid Regurgitation using smaller diameter lead and placing the lead on the proximal septum.12 months

Secondary

MeasureTime frame
Left Ventricular lead placement will be associated with least amount of TR because of avoiding crossing the tricuspid valve and by virtue of relatively more synchronous ventricular contractions.12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026